Posted in | News | Medical Sensor

FDA Clearance for Asthmapolis’ Asthma Inhaler Sensor

Asthmapolis, a company focused on improving asthma management for patients and healthcare professionals, has achieved a milestone by securing the U.S. Food and Drug Administration (FDA) clearance to market its asthma inhaler sensor technology and related software system.

The Asthmapolis sensor sits easily on top of most inhalers.

The sensor is fixed on top of inhalers, utilized by patients with COPD and asthma. When a patient uses an inhaler, the sensor system works along with a mobile phone application to collect information about everyday management. The tools, including web and mobile phone applications, offer a better understanding of patterns and triggers in asthma symptoms in individuals and communities and also enhance awareness of disease control. In addition, the data collected by the sensor is used to deliver personalized guidance and education.

Inger Couture, Asthmapolis’ Chief Regulatory Officer, noted that the FDA clearance supports their aim of delivering tools that help patients and healthcare professionals to better understand and control asthma symptoms. The inhaler sensor technology from the company helps track symptoms and use of metered dose inhalers in a much easier way, thus enabling patients and their families and doctors to get a valuable perception on asthma.

The Co-Founder and CEO of the company, David Van Sickle noted that additionally, the technology provides physicians the capability to rapidly identify the health of their patients and take necessary steps to control their disease.

The tracking of inhaler on the basis on geography can provide valuable information on environmental factors that cause acute events in different patients. Thus, preventing such environments will further enhance overall asthma control and decrease healthcare costs, remarked Robert F. Lemanske from the University of Wisconsin School of Medicine and Public Health.

Source: http://asthmapolis.com/

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kaur, Kalwinder. (2019, February 24). FDA Clearance for Asthmapolis’ Asthma Inhaler Sensor. AZoSensors. Retrieved on May 02, 2024 from https://www.azosensors.com/news.aspx?newsID=4469.

  • MLA

    Kaur, Kalwinder. "FDA Clearance for Asthmapolis’ Asthma Inhaler Sensor". AZoSensors. 02 May 2024. <https://www.azosensors.com/news.aspx?newsID=4469>.

  • Chicago

    Kaur, Kalwinder. "FDA Clearance for Asthmapolis’ Asthma Inhaler Sensor". AZoSensors. https://www.azosensors.com/news.aspx?newsID=4469. (accessed May 02, 2024).

  • Harvard

    Kaur, Kalwinder. 2019. FDA Clearance for Asthmapolis’ Asthma Inhaler Sensor. AZoSensors, viewed 02 May 2024, https://www.azosensors.com/news.aspx?newsID=4469.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.